![Peter Dritschilo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Dritschilo
Präsident bei SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Vermögen: 3 483 $ am 31.05.2024
Aktive Positionen von Peter Dritschilo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Präsident | 18.12.2012 | - |
Geschäftsführer | 18.12.2012 | - | |
Direktor/Vorstandsmitglied | 18.12.2012 | - | |
Shuttle Pharmaceuticals, Inc.
![]() Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Geschäftsführer | 01.12.2012 | - |
Präsident | 01.12.2012 | - |
Karriereverlauf von Peter Dritschilo
Ausbildung von Peter Dritschilo
Georgetown University | Undergraduate Degree |
The GW School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Chief Operating Officer | 2 |
President | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Shuttle Pharmaceuticals, Inc.
![]() Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
- Börse
- Insiders
- Peter Dritschilo
- Erfahrung